VADUZ, Liechtenstein, April 30, 2024 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, reports many presentations including new RefluxStop™ real-world data from over 200 patients at five hospitals across Europe, were presented in Scientific Sessions at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Annual Scientific Meeting..

列支敦士登瓦杜兹，2024年4月30日/PRNewswire/--Implantica AG（publ。）是一家领先于将先进技术引入人体的医疗技术公司，报告了许多演讲，包括来自欧洲五家医院200多名患者的新RefluxStop™真实世界数据，在美国胃肠道和内镜外科医生协会（SAGES）年度科学会议的科学会议上发表。。

This highly esteemed conference is the biggest meeting in the world dedicated specifically to gastrointestinal and endoscopic surgery. Some 2,500 SAGES members, representing the world-leading experts in gastrointestinal and endoscopic surgery, attended the SAGES Annual Meeting in Cleveland, Ohio on April 17-20..

这次备受尊敬的会议是世界上最大的专门讨论胃肠道和内镜手术的会议。约2500名SAGES成员代表世界领先的胃肠道和内镜手术专家，参加了4月17日至20日在俄亥俄州克利夫兰举行的SAGES年会。。

It's a credit to the ongoing enthusiasm for RefluxStop™ to see the latest clinical data from five world-renowned European centers of excellence in the treatment of acid reflux diseases, presented at SAGES. The Centers of Excellence included the following:

能够在SAGES上看到五个世界著名的欧洲酸反流病治疗卓越中心的最新临床数据，是对RefluxStop™持续热情的赞扬。卓越中心包括：

Krankenhaus Nordwest GmbH, Frankfurt, Germany Presenting author: Dr. Moustafa Elshafei

德国法兰克福Krankenhaus Nordwest GmbH演示作者：Moustafa Elshafei博士

Hirslanden Beau-Site Hospital, Bern, Switzerland Presenting author: Dr. Joerg Zehetner

瑞士伯尔尼Hirslanden Beau Site医院介绍作者：Joerg Zehetner博士

Inselspital, University Hospital, Bern, Switzerland Presenting author: Dr. Yves Borbély

瑞士伯尔尼大学医院Inselspital介绍作者：Yves Borbély博士

AKH University Hospital Vienna, AustriaPresenting author: Prof. Dr. Sebastian Schoppmann

澳大利亚维也纳AKH大学医院介绍作者：SebastianSchoppmann教授

Clinics for General and Visceral Surgery, Klinikum Friedrichshafen, GermanyPresenting author: Dr. Thortsen G. Lehmann

普通和内脏外科诊所，德国Klinikum Friedrichshafen介绍作者：Thortsen G.Lehmann博士

Dr. Peter Forsell, CEO of Implantica says, 'The excellent real-world outcomes from a dataset that is four times bigger than the size of the CE study conducted more than five years ago is a strong validation of the consistent and sustained outcomes of the RefluxStop therapy. This research further establishes RefluxStop™ as an exceptional surgical treatment for GERD, setting the stage for strong future growth in US once we get market approval.'.

Implantica首席执行官彼得·福塞尔（PeterForsell）博士说，“一个比五年前进行的CE研究规模大四倍的数据集取得了出色的现实结果，有力地验证了回流停止疗法的一致性和持续性。这项研究进一步将RefluxStop™确立为GERD的一种特殊手术治疗方法，一旦我们获得市场认可，将为美国未来的强劲增长奠定基础。”。

Dr. Forsell goes on to say, 'There has been an immense interest and support in RefluxStop™ therapy from the US surgeons and scientific experts. Looking to the US market where 20% of the adult population suffers from GERD1, we see a massive opportunity for the innovative RefluxStop™ procedure to transform patients' quality of life, pending FDA approval.'.

福塞尔博士接着说，“美国外科医生和科学专家对RefluxStop™治疗产生了极大的兴趣和支持。展望20%的成年人口患有GERD1的美国市场，我们看到创新的RefluxStop™程序有巨大的机会来改变患者的生活质量，等待FDA批准。

Fass R, Frazier R. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease. Therap Adv Gastroenterol. 2017 Feb;10(2):243-251. doi: 10.1177/1756283X16681701. Epub 2017 Jan 5. PMID: 28203282; PMCID: PMC5298478.

Fass R，Frazier R.右兰索拉唑修饰释放在胃食管反流病治疗中的作用。Therap Adv Gastroenterol。2017年2月；10（2）：243-251。doi:10.1177/1756283X16681701。Epub 2017年1月5日。PMID:28203282；PMCID:PMC5298478。

For further information, please contact:Nicole Pehrsson, Chief Corporate Affairs OfficerTelephone (CH): +41 (0)79 335 09 49nicole.pehrsson@implantica.com

欲了解更多信息，请联系：首席企业事务办公室Nicole Pehrsson电话（CH）：+41（0）79 335 0949nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

Implantica在斯德哥尔摩的Nasdaq First North Premier成长市场上市。

The company's Certified Adviser is FNCA Sweden AB, info@fnca.se

该公司的注册顾问是FNCA瑞典AB，info@fnca.se

The information was sent for publication, through the agency of the contact person set out above, on April 30, 2024, at 08:00 a.m. (CET).

该信息于2024年4月30日上午08:00（CET）通过上述联系人的代理发送发布。

About Implantica

关于Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results.

Implantica是一家致力于将先进技术引入人体的医疗技术集团。Implantica的主要产品RefluxStop™是一种CE标记的植入物，用于预防胃食管反流，这将有可能在成功的临床试验结果支持下产生抗反流治疗的范式转变。

Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energizing platform designed to power remote-controlled implants wirelessly through intact skin.

Implantica还专注于体内电子健康，并开发了一个广泛的、受专利保护的产品线，部分基于两种平台技术：一个电子健康平台，旨在监测广泛的健康参数，控制体内治疗，并与远程护理人员进行通信，另一个无线激励平台，旨在通过完整的皮肤无线遥控植入物。

Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information..

Implantica在Nasdaq First North Premier Growth Market（股票代码：IMP A SDB）上市。有关更多信息，请访问www.implantica.com。。

About RefluxStop™

关于RefluxStop™

RefluxStop™ is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. It's unique mechanism of action differentiates it from standard of care and current surgical solutions. Longer established surgical options for GERD involve encircling the food passageway to support the lower esophageal sphincter's closing mechanism and are commonly associated with side effects such as swallowing difficulties, pain when swallowing and inability to belch and/or vomit..

RefluxStop™是一种新的创新疗法，有可能刺激抗反流手术的范式转变。它独特的作用机制使其区别于标准护理和当前的手术解决方案。GERD的长期手术选择包括包围食物通道以支持食管下括约肌的闭合机制，并且通常与吞咽困难，吞咽时疼痛以及无法打嗝和/或呕吐等副作用有关。。

In contrast, the RefluxStop device treats the cause of acid reflux without encircling and putting pressure on the food passageway. It restores and maintains the lower esophageal sphincter in its original, natural position.

相反，回流停止装置处理酸回流的原因，而不会包围并对食物通道施加压力。它将食管下括约肌恢复并保持在其原始的自然位置。

The RefluxStop™ mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux..

RefluxStop™作用机制的重点是重建抗回流屏障的所有三个组成部分，如果受损，可能会导致酸回流。它恢复并支持身体的自然解剖生理，使身体能够自行解决酸反流的问题。。

Newsroomhttps://www.implantica.com/media/media-kit

Newsroomhttps://www.implantica.com/media/media-kit

Communityhttps://ch.linkedin.com/company/implanticahttps://www.twitter.com/implantica

Communityhttps://ch.linkedin.com/company/implanticahttps://www.twitter.com/implantica

Media Contact:Juanita Eberhart, VP Marketing & AdvocacyM: +1 925-381-4581juanita.eberhart@implantica.com

媒体联系人：胡安妮塔·埃伯哈特（Juanita Eberhart），营销和广告副总裁：+1925-381-4581juanita.eberhart@implantica.com

This information was brought to you by Cision http://news.cision.com

此信息由Cision提供给您http://news.cision.com

https://news.cision.com/implantica/r/implantica-announces-real-world-clinical-data-from-over-200-patients-treated-across-five-refluxstop-,c3970435

https://news.cision.com/implantica/r/implantica-announces-real-world-clinical-data-from-over-200-patients-treated-across-five-refluxstop-，c3970435

The following files are available for download:

以下文件可供下载：

https://mb.cision.com/Main/19732/3970435/2769366.pdf

https://mb.cision.com/Main/19732/3970435/2769366.pdf

Implantica Announces Real-World Clinical Data from over 200 Patients treated across five RefluxStop™ Centers in Europe Presented at SAGES in Cleveland

Implantica公布了在克利夫兰SAGES上展示的欧洲五个RefluxStop™中心接受治疗的200多名患者的真实临床数据